Celltrion Inc
KRX:068270
Celltrion Inc's latest stock split occurred on Dec 27, 2024
The company executed a 1-for-1 stock split, meaning that for every share held, investors received 1 new share.
Before the split, Celltrion Inc traded at 191500.0008 per share. Afterward, the share price was about 180400.
The adjusted shares began trading on Dec 27, 2024. This was Celltrion Inc's 17th stock split, following the previous one in Dec 28, 2022.
WKSP
NAYA
300803
WKHS
Celltrion Inc
Glance View
Celltrion Inc. stands as a significant player in the global biopharmaceutical industry, rooted in the heart of South Korea's bustling innovation scene. Founded in 2002 by Seo Jung-Jin, the company initially carved its niche in the development of biosimilars, which are near-identical versions of original biological drugs whose patents have expired. With rapid advancements in biotechnology, Celltrion has well-positioned itself to tap into the expanding market for affordable and accessible biologic treatments. At the core of its operation is its cutting-edge production facilities equipped with high-tech fermentation and purification processes necessary for manufacturing these complex medicines. This foundational expertise has allowed Celltrion to pioneer some of the world's first monoclonal antibody biosimilars, including those for autoimmune diseases and oncological conditions, thereby cementing its reputation as a forerunner in global biosimilar development. The company’s revenue model is intricately tied to its production capabilities and strategic partnerships. By leveraging its advanced manufacturing infrastructure, Celltrion not only produces its own line of biosimilars but also collaborates with global pharmaceutical companies to license and distribute its products worldwide. Such partnerships have enabled Celltrion to penetrate markets across Europe, the Americas, and Asia, with its biosimilars gaining regulatory approval in many regions. Furthermore, Celltrion’s business is not limited to biosimilars; it is actively investing in novel biologics and innovative delivery systems. This diversification strategy underscores its commitment to sustainable growth and reducing dependence on any single product line, ultimately fostering a robust pipeline that promises to meet the healthcare industry's evolving demands.
You don't have any saved screeners yet